Publications by authors named "G A Pattee"
Article Synopsis
- ALSUntangled examines alternative treatments for ALS, focusing on psilocybin, a psychedelic compound from mushrooms.
- Psilocybin may theoretically help slow ALS due to its ability to cross the blood-brain barrier and influence neurogenesis and inflammation, but there's no existing research specifically on its effects in ALS patients.
- Due to potential risks of psychological side effects and lack of supporting evidence, the use of psilocybin for ALS progression is not currently endorsed.
Understanding the molecular mechanisms which drive and modulate host-pathogen interactions are essential when designing effective therapeutic and diagnostic approaches aimed at controlling infectious diseases. Certain large and giant viruses have recently been discovered as components of the human virome, yet little is known about their interactions with the host immune system. We have dissected the role of viral N-linked glycans during the interaction between the glycoproteins from six chloroviruses (belonging to three chlorovirus classes: NC64A, SAG, and Osy viruses) and the representative carbohydrate-binding receptors of the innate immune system.
View Article and Find Full Text PDFArticle Synopsis
- - The Wahls diet is a specialized version of the Paleolithic diet, focusing on nutrient-rich foods like leafy greens and omega-3 fatty acids while limiting processed foods and sugars, aiming to reduce inflammation and oxidative stress.
- - While some studies link components of the Wahls diet, like high carotenoids and omega-3s, to reduced ALS risk, there is no solid evidence proving it slows ALS progression, with conflicting results from animal model research.
- - Additionally, the Wahls diet has led to significant weight loss in people with multiple sclerosis, raising concerns since weight loss can worsen ALS, leading to the conclusion that the diet shouldn't be endorsed for ALS patients.
Article Synopsis
- The study investigates the safety, tolerability, and pharmacokinetics of BIIB078, an investigational treatment targeting the genetic cause of amyotrophic lateral sclerosis (ALS) linked to the C9orf72 gene mutation.
- The trial involved 106 participants with C9orf72-associated ALS, who were randomly assigned to receive varying doses of BIIB078 or a placebo over a treatment period of three to six months.
- Results showed that all participants experienced at least one adverse event, mostly mild or moderate, indicating that while BIIB078 did pose some risks, it did not lead to a high rate of treatment discontinuation.